Coherus Biosciences Inc
CHRS
Get informed when a big investor buys or sells
+ FollowMarket Cap$185.4M
Close$
$-0.29
125.6% downside
Current Fair Value
125.6% downsideOvervalued by 125.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $185.40 Million |
|---|---|
| Enterprise Value | $140.18 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.45 |
| Beta | 0.98 |
| Outstanding Shares | 154,816,912 |
Return
| Return on Equity | -772.64% |
|---|---|
| Return on Assets | -245.87% |
| Return on Invested Capital | -139.20% |
Valuation & Multiples
| P/E Ratio | -1.18 |
|---|---|
| PEG | 1.1 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 2.75 |
| Enterprise Value to EBIT | -0.87 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.27 |
| Debt to Equity | 0.62 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 6, 2026
EPS Estimate
$-0.12
Average shareholder expectationRevenue Estimate
$14.41 M
Average shareholder expectationNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$-0.20
Average shareholder expectationRevenue Estimate
$15.98 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 485.91% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 24.18%▼ 19.28% |
|---|---|
| Total Invested | $46.17M▼ 53.84% |
| Investors Holding | 51▼ 110.00% |
ESG Score
No data
About Coherus Biosciences Inc
CEO: Dennis Lanfear